Mirum Pharmaceuticals
$40.7
21
-$0.83-2% Friday 20:00
Statistics
Day High
41.6
Day Low
40.51
52W High
44.94
52W Low
23.14
Volume
454,215
Avg. Volume
641,469
Mkt Cap
1.94B
P/E Ratio
-16.96
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6NovConfirmed
Expected EPS
-0.431434
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MIRM. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap120.91B
Alnylam Pharmaceuticals
ALNY
Mkt Cap34.6B
Gilead Sciences
GILD
Mkt Cap91.71B
Abbvie
ABBV
Mkt Cap335.48B
Pfizer
PFE
Mkt Cap161.78B
Novartis
NVS
Mkt Cap245.03B
Merck
MRK
Mkt Cap290.13B
Astrazeneca
AZN
Mkt Cap251.73B
Bristol-Myers Squibb
BMY
Mkt Cap94.72B
Analyst Ratings
57.3$Average Price Target
The highest estimate is $68.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
90%
Hold
10%
Sell
0%
About
Health Technology
Pharmaceuticals: Major
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Show more...
CEO
Employees
294
Country
US
ISIN
US6047491013
WKN
000A2PM29